Dexcom and Abbott are both racing to gain control of the continuous glucose monitor (CGM) market in 2023.
Dexcom Tries To Close Gap On Abbott in CGM
The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.
More from Diabetic Care
More from Device Area
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.
• By
Roche Diagnostics CEO Matthew Sause tells Medtech Insight about how the technology addresses the pricing challenges for mid- and low-throughput customers.
• By
A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.